Evidence map›Paper›PMID 26081345›Full record

ArticleArthritis research & therapy2015

Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.

Annemarie E M van Nieuwenhuijze, Fons A van de Loo, Birgitte Walgreen, Miranda Bennink, Monique Helsen, Liduine van den Bersselaar, Ian P Wicks, Wim B van den Berg, Marije I Koenders

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Review
  3. Extracellular vesicles as tools and targets in therapy for diseases.Signal transduction and targeted therapy · 2024
    Review
  4. Combination treatment with interferon-γ may be a potential strategy to improve the efficacy of cytotherapy for rheumatoid arthritis: A network meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Exosome: Function and Application in Inflammatory Bone Diseases.Oxidative medicine and cellular longevity · 2021
    Review
  10. Generation of a novel CD30Clinical and experimental immunology · 2020
    Article
  11. GM-CSF in inflammation.The Journal of experimental medicine · 2020
    Review
  12. Review
  13. Review
  14. miR-21-5p protects IL-1β-induced human chondrocytes from degradation.Journal of orthopaedic surgery and research · 2019
    Article
  15. Article
  16. Article
  17. Review
  18. Novel Therapeutic Targets in Axial Spondyloarthritis.Current treatment options in rheumatology · 2018
    Review
  19. Selected cytokine pathways in rheumatoid arthritis.Seminars in immunopathology · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Annemarie E M van NieuwenhuijzeExperimental Rheumatology, Radboud University Medical Centre, Route 272, Geert Grooteplein 28, 6525, GA, Nijmegen, The Netherlands. annemarie.vannieuwenhuijze@vib-kuleuven.be.
Fons A van de LooExperimental Rheumatology, Radboud University Medical Centre, Route 272, Geert Grooteplein 28, 6525, GA, Nijmegen, The Netherlands. fons.vandeloo@radboudumc.nl.
Birgitte WalgreenExperimental Rheumatology, Radboud University Medical Centre, Route 272, Geert Grooteplein 28, 6525, GA, Nijmegen, The Netherlands. birgitte.walgreen@radboudumc.nl.
Miranda BenninkExperimental Rheumatology, Radboud University Medical Centre, Route 272, Geert Grooteplein 28, 6525, GA, Nijmegen, The Netherlands. miranda.bennink@radboudumc.nl.
Monique HelsenExperimental Rheumatology, Radboud University Medical Centre, Route 272, Geert Grooteplein 28, 6525, GA, Nijmegen, The Netherlands. monique.helsen@radboudumc.nl.
Liduine van den BersselaarExperimental Rheumatology, Radboud University Medical Centre, Route 272, Geert Grooteplein 28, 6525, GA, Nijmegen, The Netherlands. liduine.vandenbersselaar@radboudumc.nl.
Ian P WicksReid Rheumatology Laboratory, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3050, Melbourne, Australia. wicks@wehi.edu.au.
Wim B van den BergExperimental Rheumatology, Radboud University Medical Centre, Route 272, Geert Grooteplein 28, 6525, GA, Nijmegen, The Netherlands. wim.vandenberg@radboudumc.nl.
Marije I KoendersExperimental Rheumatology, Radboud University Medical Centre, Route 272, Geert Grooteplein 28, 6525, GA, Nijmegen, The Netherlands. marije.koenders@radboudumc.nl.
Radboud University Medical Center · NLRadboud University Nijmegen · NLWalter and Eliza Hall Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionType 17 T helper cells and interleukin (IL)-17 play important roles in the pathogenesis of human and murine arthritis. Although there is a clear link between IL-17 and granulocyte macrophage colony-stimulating factor (GM-CSF) in the inflammatory cascade, details about their interaction in arthritic synovial joints are unclear. In view of the introduction of GM-CSF and IL-17 inhibitors to the clinic, we studied how IL-17 and GM-CSF orchestrate the local production of inflammatory mediators during experimental arthritis.

methodsTo allow detection of additive, complementary or synergistic effects of IL-17 and GM-CSF, we used two opposing experimental approaches: treatment of arthritic mice with neutralising antibodies to IL-17 and GM-CSF and local overexpression of these cytokines in naive synovial joints. Mice were treated for 2 weeks with antibodies against IL-17 and/or GM-CSF after onset of collagen-induced arthritis. Naive mice were injected intraarticularly with adenoviral vectors for IL-17 and/or GM-CSF, resulting in local overexpression. Joint inflammation was monitored by macroscopic scoring, X-rays and histology. Joint washouts, synovial cell and lymph node cultures were analysed for cytokines, chemokines and inflammatory mediators by Luminex analysis, flow cytometry and quantitative polymerase chain reaction.

resultsCombined therapeutic anti-IL-17 and anti-GM-CSF ameliorated arthritis progression, and joint damage was dramatically reduced compared with treatment with anti-IL-17 or anti-GM-CSF alone. Anti-IL-17 specifically reduced synovial IL-23 transcription, whereas anti-GM-CSF reduced transcription of matrix metalloproteinases (MMPs) and receptor activator of nuclear factor κB ligand (RANKL). Overexpression of IL-17 or GM-CSF in naive knee joints elicited extensive inflammatory infiltrate, cartilage damage and bone destruction. Combined overexpression revealed additive and synergistic effects on the production of MMPs, RANKL and IL-23 in the synovium and led to complete destruction of the joint structure within 7 days.

conclusionsIL-17 and GM-CSF differentially mediate the inflammatory process in arthritic joints and show complementary and local additive effects. Combined blockade in arthritic mice reduced joint damage not only by direct inhibition of IL-17 and GM-CSF but also by indirect inhibition of IL-23 and RANKL. Our results provide a rationale for combination therapy in autoinflammatory conditions, especially for patients who do not fully respond to inhibition of the separate cytokines.

Indexed as

AnimalsArthritis, ExperimentalArthritis, RheumatoidBone and BonesCartilage, ArticularFlow CytometryGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-17Interleukin-23MaleMatrix MetalloproteinasesMiceReal-Time Polymerase Chain ReactionReceptor Activator of Nuclear Factor-kappa BSignal TransductionTh17 CellsGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-17Interleukin-23Matrix MetalloproteinasesReceptor Activator of Nuclear Factor-kappa B

Identifiers

PMID26081345
PMCPMC4496892
OpenAlexW1495088797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.